Tricida, Inc., a South San Francisco, CA-based clinical stage, biopharmaceutical company focused on the discovery and development of chronic therapies for patients with chronic kidney disease (CKD), raised $55M Series C funding round.
The round was led by new investor Longitude Capital, with participation from new investor Vivo Capital and existing investors OrbiMed, Sibling Capital Ventures and Limulus Venture Partners. In conjunction with the funding, David Hirsch, M.D., Ph.D., Managing Director at Longitude, joined the Tricida Board.
The company has raised $95M in total funding.
Led by Gerrit Klaerner, Ph.D., CEO and President, Tricida is advancing TRC101, a chronic treatment for complications of renal disease. The company is on track to complete a first-in-human 100 patient phase 1/2 study and is preparing to discuss the safety and efficacy results from the study with the FDA in a Type B meeting later this year.